Listed

Sanofi: Form 20-F for the period ended Dec 31, 2020

Filed with the SEC on Mar 4, 2021 and accepted by EDGAR at Mar 4, 2021, 10:22 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue12 months2020-01-01 to 2020-12-31EUR 12.16bnifrs-full:CostOfSales
Gross profit12 months2020-01-01 to 2020-12-31EUR 25.21bnifrs-full:GrossProfit
Operating income12 months2020-01-01 to 2020-12-31EUR 14.14bnifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2020-01-01 to 2020-12-31EUR 1.81bnifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2020-01-01 to 2020-12-31EUR 12.31bnifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2020-01-01 to 2020-12-31EUR 9.77ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2020-01-01 to 2020-12-31EUR 9.82ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2020-01-01 to 2020-12-31EUR 7.45bnifrs-full:CashFlowsFromUsedInOperatingActivities
Cash and equivalentsAt period end2020-12-31EUR 13.91bnifrs-full:CashAndCashEquivalents
Total assetsAt period end2020-12-31EUR 114.53bnifrs-full:Assets
Shareholders' equityAt period end2020-12-31EUR 63.00bnifrs-full:EquityAttributableToOwnersOfParent
Shares outstandingAt period end2020-12-311,250,690,553 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001121404-21-000004. Last ingested by Listed: Nov 5, 2026, 12:26 ET. Listed shows no prices and gives no investment advice.